BTF granted US patent for 'Bioballs'
Thursday, 23 September, 2004
Private Sydney-based biotech BTF has been granted a US patent for its BioBall quality-control product.
The patent protects its BioBall technology, which uses a flow cytometer to count out precisely 30 viable bacteria. The bacteria are freeze dried in a drop of nutrient fluid as a 'Bioball' pellet.
The pellets can be reconstituted and used as a control, eliminating the need for labs to perform routine serial dilutions.
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
